Company intelligence / Profile preview
Fedora Pharmaceuticals Inc.
Edmonton, Alberta, Canadafedorapharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Nacubactam (formerly FPI-1459) has completed several Phase 1 clinical trials and is available for licensing as a combination product with meropenem[7][9]
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculesbeta-lactamase inhibitors
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Meiji Seika PharmaRoche (previous licensing deal)[7]
Beyond the preview
Go deeper on Fedora Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fedora Pharmaceuticals Inc..